Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 14;4(8):1612-30.
doi: 10.3390/jcm4081612.

Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients

Véronique C LeBlanc  1 , Pier Morin  2
Affiliations
Review

Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients

Véronique C LeBlanc et al. J Clin Med. .

Abstract

The growing attention that non-coding RNAs have attracted in the field of cancer research in recent years is undeniable. Whether investigated as prospective therapeutic targets or prognostic indicators or diagnostic biomarkers, the clinical relevance of these molecules is starting to emerge. In addition, identification of non-coding RNAs in a plethora of body fluids has further positioned these molecules as attractive non-invasive biomarkers. This review will first provide an overview of the synthetic cascade that leads to the production of the small non-coding RNAs microRNAs (miRNAs) and presents their strengths as biomarkers of disease. Our interest will next be directed at exploring the diagnostic utility of miRNAs in two types of cancer: the brain tumor glioblastoma multiforme (GBM) and breast cancer. Finally, we will discuss additional clinical implications associated with miRNA detection as well as introduce other non-coding RNAs that have generated recent interest in the cancer research community.

Keywords: breast cancer; cancer diagnosis; cancer therapeutics; glioblastoma multiforme; glioma; long non-coding RNAs; microRNAs; non-coding RNAs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MiR-21 validated targets in glioblastoma multiforme and breast cancer studies. Targets in breast cancer are shown in pink and targets in glioblastoma multiforme are shown in gray.
Figure 2
Figure 2
MiR-221/222 validated targets in glioblastoma multiforme and breast cancer studies. Targets in breast cancer are shown in pink and targets in glioblastoma multiforme are shown in gray. * Targets regulated by miR-221 alone. ** Target regulated by miR-222 alone.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Leivonen S.K., Sahlberg K.K., Mäkelä R., Due E.U., Kallioniemi O., Børresen-Dale A.L., Perälä M. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol. Oncol. 2014;8:93–104. doi: 10.1016/j.molonc.2013.10.001. - DOI - PMC - PubMed
    1. Rupaimoole R., Wu S.Y., Pradeep S., Ivan C., Pecot C.V., Gharpure K.M., Nagaraja A.S., Armaiz-Pena G.N., McGuire M., Zand B., et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat. Commun. 2014;5 doi: 10.1038/ncomms6202. - DOI - PMC - PubMed
    1. Valeri N., Braconi C., Gasparini P., Murgia C., Lampis A., Paulus-Hock V., Hart J.R., Ueno L., Grivennikov S.I., Lovat F., et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell. 2014;25:469–483. doi: 10.1016/j.ccr.2014.03.006. - DOI - PMC - PubMed
    1. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006. doi: 10.1038/cr.2008.282. - DOI - PubMed
    1. Kodahl A.R., Lyng M.B., Binder H., Cold S., Gravgaard K., Knoop A.S., Ditzel H.J. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Mol. Oncol. 2014;8:874–883. doi: 10.1016/j.molonc.2014.03.002. - DOI - PMC - PubMed

LinkOut - more resources